A detailed history of Dimensional Fund Advisors LP transactions in Repare Therapeutics Inc. stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 13,265 shares of RPTX stock, worth $17,509. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,265
Previous 13,265 -0.0%
Holding current value
$17,509
Previous $43,000 4.65%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$3.02 - $4.7 $83,062 - $129,268
-27,504 Reduced 67.46%
13,265 $43,000
Q1 2024

May 10, 2024

SELL
$4.53 - $8.41 $14,939 - $27,736
-3,298 Reduced 7.48%
40,769 $192,000
Q4 2023

Feb 07, 2024

SELL
$3.22 - $11.79 $23,080 - $84,510
-7,168 Reduced 13.99%
44,067 $321,000
Q3 2023

Nov 09, 2023

SELL
$8.16 - $13.01 $29,433 - $46,927
-3,607 Reduced 6.58%
51,235 $618,000
Q2 2023

Aug 09, 2023

BUY
$8.63 - $12.53 $690 - $1,002
80 Added 0.15%
54,842 $580,000
Q1 2023

May 12, 2023

BUY
$9.32 - $15.06 $14,697 - $23,749
1,577 Added 2.97%
54,762 $538,000
Q4 2022

Feb 09, 2023

BUY
$12.5 - $18.13 $502,575 - $728,934
40,206 Added 309.78%
53,185 $782,000
Q3 2022

Nov 10, 2022

SELL
$11.57 - $15.59 $333,991 - $450,036
-28,867 Reduced 68.98%
12,979 $157,000
Q2 2022

Aug 12, 2022

SELL
$8.45 - $14.84 $67,304 - $118,200
-7,965 Reduced 15.99%
41,846 $585,000
Q1 2022

May 13, 2022

SELL
$11.38 - $21.88 $18,492 - $35,555
-1,625 Reduced 3.16%
49,811 $709,000
Q4 2021

Feb 09, 2022

BUY
$19.66 - $28.11 $239,753 - $342,801
12,195 Added 31.08%
51,436 $1.09 Million
Q3 2021

Nov 12, 2021

BUY
$25.71 - $35.24 $1.01 Million - $1.38 Million
39,241 New
39,241 $1.03 Million

Others Institutions Holding RPTX

About Repare Therapeutics Inc.


  • Ticker RPTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,937,800
  • Market Cap $55.4M
  • Description
  • Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that foc...
More about RPTX
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.